Evaluation of factors influencing adherence to treatment with sodium-glucose cotransporter type 2 inhibitor
https://doi.org/10.20538/1682-0363-2020-3-44-51
Abstract
Despite the emergence of new groups of drugs for the treatment of type 2 diabetes mellitus (DM2), the issue of optimal adherence to treatment remains of interest.
The aim of this study was to investigate the factors that influence the adherence to treatment with sodium glucose co-transporter type 2 inhibitor, empagliflozin (Jardiance, Boehringer Ingelheim, Germany), in patients with DM2.
Materials and methods. The study included 102 patients with DM2 (58 of them were women); the observation time was 24 weeks. The mean age was 58.3 ± 10.4 years.
Results. Patients without cognitive impairment had a lower level of glycated hemoglobin (HbA1c) (7.76%, 6.18–9.34) than patients with mild dementia (8.51%, 7.02–10; p = 0.032). In the group of patients who noted the impossibility of purchasing even a part of the drugs, the level of HbA1c was 9.73% (8.95–10.51), while patients who had no difficulties in purchasing drugs HbA1c was 8.83% (7.85–9.81; p = 0.036). Empagliflozin was discontinued in 38.2% of patients for the following reasons: cost of the drug (16.6%), development of side effects (10.7%), lack of effectiveness (7.8%), other reasons (2.9%).
Conclusion. Thus, the main factors influencing the adherence to treatment were the cost of the drug, development of adverse events, and lack of effectiveness from the therapy. At the same time, the opportunity of purchasing all the necessary drugs was associated with both better glycemic control and a higher quality of life.
Keywords
diabetes mellitus,
adherence to treatment,
sodium glucose co-transporter type 2 inhibitor,
empagliflozin
Supporting agencies: The study was carried out with the financial support of the Russian Science Foundation, grant No. 17-75-30052.
About the Authors
D. A. Lebedev
Institute of Endocrinology, Almazov National Medical Research Center
Russian Federation
15, Parkhomenko Str., Saint-Petersburg, 194156, Russian Federation
Russian Federation
15, Parkhomenko Str., Saint-Petersburg, 194156, Russian Federation
A. A. Mosikian
Institute of Endocrinology, Almazov National Medical Research Center
Russian Federation
15, Parkhomenko Str., Saint-Petersburg, 194156, Russian Federation
Russian Federation
15, Parkhomenko Str., Saint-Petersburg, 194156, Russian Federation
A. Yu. Babenko
Institute of Endocrinology, Almazov National Medical Research Center
Russian Federation
15, Parkhomenko Str., Saint-Petersburg, 194156, Russian Federation
Russian Federation
15, Parkhomenko Str., Saint-Petersburg, 194156, Russian Federation
References
1. International Diabetes Federation, IDF diabetes atlas 2017. URL: http://www.diabetesatlas.org/IDF_Diabetes_Atlas_8e_interactive_EN/
2. Grundy S.M., Benjamin I.J., Burke G.L. et al. Diabetes and cardiovascular disease a statement for health care professionals from the American Heart Association. Circulation. 1999; 100 (10): 1134–1146. DOI: 10.1161/01.CIR.100.10.1134.
3. Patel A., Mac Mahon S., Chalmers J., Neal B. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2008; 358 (24): 2560–2572. DOI: 10.1056/NEJMoa0802987.
4. Ismail-Beigi F., Craven T., Banerji M.A., Basile J. et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010; 376 (9739): 419–430. DOI: 10.1016/S0140-6736(10)60576-4.
5. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008; 359 (15): 1577– 1589. DOI: 10.1056/NEJMoa0806470.
6. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D. et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 2009; 360 (2): 129–139. DOI: 10.1056/NEJMoa0808431.
7. Al-Qazaz H.K., Sulaiman S.A., Hassali M.A. et al. Diabetes knowledge, medication adherence and glycemic control among patients with type 2 diabetes. Int. J. Clin. Pharm. 2011; 33 (6): 1028–1035. DOI: 10.1007/s11096-011-9582-2.
8. Hess L.M., Raebel M.A., Conner D.A., Malone D.C. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann. Pharmacother. 2006; 40 (7–8): 1280–1288. DOI: 10.1345/aph.1H018.
9. World Health Organization. Adherence to long-term therapies. Evidence for action. URL: http://www.who.int/chp/knowledge/publications/adherence_introduction.pdf. Published 2003. (аccessed February 8, 2017).
10. Farr A.M., Sheehan J.J., Curkendall S.M. et al. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus. Adv. Ther. 2014; 31 (12): 1287–1305. DOI: 10.1007/s12325-014-0171-3.
11. Cramer J.A., Benedict A., Muszbek N. et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int. J. Clin. Pract. 2008; 62 (1): 76–87. DOI: 10.1111/j.1742-1241.2007.01630x.
12. Vietri J.T., Wlodarczyk C.S., Lorenzo R. et al. Missed doses of oral antihyperglycemic medications in US adults with type 2 diabetes mellitus: prevalence and self-reported reasons. Curr. Med. Res. Opin. 2016; 32 (9): 1519–1527. DOI: 10.1080/03007995.2016.1186614.
13. Bonafede M.M., Kalsekar A., Pawaskar M., Ruiz K.M. et al. A retrospective database analysis of insulin use patterns in insulin-naive patients with type 2 diabetes initiating basal insulin or mixtures. Patient Prefer Adherence. 2010; 4: 147–156. DOI: 10.2147ppa.s10467.
14. Iglay K., Cartier S.E., Rosen V.M. et al. Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes. Curr. Med. Res. Opin. 2015; 31 (7): 1283–1296. DOI: 10.1185/03007995.2015.1053048.
15. Cramer J.A. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004; 27 (5): 1218–1224. DOI: 10.2337/diacare.27.5.1218.
16. Asche C., LaFleur J., Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin. Ther. 2011; 33 (1): 74–109. DOI: 10.1016/j.clinthera.2011.01.019.
17. Kirkman M.S., Rowan-Martin M.T., Levin R. et al. Determinants of adherence to diabetes medications: findings from a large pharmacy claims database. Diabetes Care. 2015; 38 (4): 604–609. DOI: 10.2337/dc14-2098.
18. Tourkmani A.M. et al. Medication adherence among patients in a chronic disease clinic. Saudi Med. J. 2012; 33 (12): 1278–1284.
19. Curkendall S.M., Thomas N., Bell K.F. et al. Predictors of medication adherence in patients with type 2 diabetes mellitus. Curr. Med. Res. Opin. 2013; 29 (10): 1275–1286. DOI: 10.1185 / 03007995.2013.821056.
20. Williams J., Steers W.N., Ettner S.L., Mangione C.M., Duru O.K. Costrelated nonadherence by medication type among medicare Part D beneficiaries with diabetes. Med. Care. 2013; 51 (2): 193–198. DOI: 10.1097/MLR.0b013e318270dc52.
21. Duberstein P., Meldrum S., Fiscella K. et al. Influences on patients’ ratings of physicians: Physicians demographics and personality. Patient Educ. Couns. 2007; 65 (2): 270–274. DOI: 10.1016/j.pec.2006.09.007.
22. Paes A.H., Bakker A., Soe-Agnie C.J. Impact of dosage frequency on patient compliance. Diabetes Care. 1997; 20 (10): 1512–1517. DOI: 10.2337/diacare.20/10/1512.
23. Ratanawongsa N., Karter A.J., Parker M.M. et al. Communication and medication refill adherence: the diabetes study of Northern California. JAMA Intern. Med. 2013; 173 (3): 210–218. DOI: 10.1001/jamainternmed.2013.1216.
24. Bains S.S., Egede L.E. Associations between health literacy, diabetes knowledge, self-care behaviors, and glycemic control in a low-income population with type 2 diabetes. Diabetes Technol. Ther. 2011; 13 (3): 6335–341. DOI: 10.1089/dia.2010.0160.
25. Alvarez Guisasola F. et al. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes. Metab. 2008; 10 (Suppl. l1): 8–15. DOI: 10.1111/j.1463-1326.2008.00881.x.
26. Laliberté F. et al. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv. Ther. 2012; 29: 675–690. DOI: 10.1007/s12325-012-0040-x
27. Liakos А., Karagiannis T., Athanasiadou E. et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes. Metab. 2014; 16 (10): 984–93. DOI: 10.1111/dom.12307.
28. Sweileh W.M., Zyoud S.H., Abu Nab’a R.J. et al. Influence of patients’ disease knowledge and beliefs about medicines on medication adherence: findings from a cross-sectional survey among patients with type 2 diabetes mellitus in Palestine. BMC Public Health. 2014; 14: 94. DOI: 10.1186/1471-2458-14-94.
29. Osborn C.Y., Egede L.E.. The relationship between depressive symptoms and medication nonadherence in type 2 diabetes: the role of social support. Gen. Hosp. Psychiatry. 2012; 34 (3): 249–53. DOI: 10.1016/j.genhosppsych.2012.01.015.
30. Grodensky C.A., Golin C.E., Ochtera R.D., Turner B.J. Systematic review: effect of alcohol intake on adherence to outpatient medication regimens for chronic diseases. J. Stud. Alcohol. Drugs. 2012; 73 (6): 899–910. DOI: 10.15288/jsad.2012.73.899.
31. Dailey G., Kim M.S., Lian J.F. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. Clin. Ther. 2001; 23 (8): 1311–1320. DOI: 10.1016/S0149-2918(01)80110-7.
Review
For citations:
Lebedev D.A., Mosikian A.A., Babenko A.Yu. Evaluation of factors influencing adherence to treatment with sodium-glucose cotransporter type 2 inhibitor. Bulletin of Siberian Medicine. 2020;19(3):44-51. https://doi.org/10.20538/1682-0363-2020-3-44-51
Views:
677
Email this article 